The vertebrate forebrain is patterned during gastrulation into telencephalic, retinal, hypothalamic and diencephalic primordia. Specification of each of these domains requires the concerted activity of combinations of transcription factors (TFs). Paradoxically, some of these factors are widely expressed in the forebrain, which raises the question of how they can mediate regional differences. To address this issue, we focused on the homeobox TF Six3.2. With genomic and functional approaches we demonstrate that, in medaka fish, Six3.2 regulates, in a concentration-dependent manner, telencephalic and retinal specification under the direct control of Sox2. Six3.2 and Sox2 have antagonistic functions in hypothalamic development. These activities are, in part, executed by Foxg1 and Rx3, which seem to be differentially and directly regulated by Six3.2 and Sox2. Together, these data delineate the mechanisms by which Six3.2 diversifies its activity in the forebrain and highlight a novel function for Sox2 as one of the main regulators of anterior forebrain development. They also demonstrate that graded levels of the same TF, probably operating in partially independent transcriptional networks, pattern the vertebrate forebrain along the anterior-posterior axis. Exploiting these advantages, here we delineate a gene regulatory network in which Six3.2 diversifies its activity in the forebrain. We demonstrate that differential expression levels of Six3.2, operating under the differential control of Sox2, are likely to pattern the forebrain by directly activating the telencephalic determinant Foxg1 (Tao and Lai, 1992) , restraining, at the same time, the expression of the hypothalamic and retinal determinant Rx3 (Deschet et al., 1999; Loosli et al., 2001; Stigloher et al., 2006) . We also show that Sox2, besides controlling Six3.2 expression, activates that of Rx3, thus establishing a four gene 'kernel' that contributes to forebrain specification.
INTRODUCTION
Vertebrate fate mapping studies have established that the telencephalon, the retinal anlage and the ventral hypothalamus derive from adjacent domains in the anterior neural plate (ANP) (SanchezArrones et al., 2009; Wilson and Houart, 2004 ). These domains are specified during gastrulation under the influence of morphogens produced by signalling centres discretely localised to the adjacent mesendoderm and in the ANP itself (Hoch et al., 2009; Wilson and Houart, 2004) . In response to the reception of morphogenetic signals, cells express specific transcription factors (TFs), which activate intrinsic cellular programmes. These, in turn, force progenitor cells to commit toward specific forebrain field identities. Many of the TFs expressed in the ANP, including Sox2, Pax6, Otx2, Rx3, Six3, Six6, Foxg1 and Emx1, have been proven essential for the proper development of each of the forebrain regions in which they are expressed (England et al., 2006; Hoch et al., 2009; Shimamura and Rubenstein, 1997; Stern, 2002; Wilson and Houart, 2004) . For some, for example Emx1 (Simeone et al., 1992) , the contribution to prosencephalic patterning is easily explained by restricted expression to a specific subdomain. Others, including Otx2, Pax6 and Six3, are more widely expressed in the forebrain (Bovolenta et al., 1998; Manuel and Price, 2005; Oliver et al., 1995; Simeone et al., 1992) or, like Sox2 (Zappone et al., 2000) , even throughout the neural tube, raising the as yet unanswered question of how their activity contributes to the identity of each particular forebrain domain in which they are expressed.
Hints to help unravel this problem come from a variety of sources. Characterisation of the regulatory regions governing Sox2, Otx2, Pax6 and Six3 expression indicates that their activity might be subject to regional and temporal-specific controls (Conte and Bovolenta, 2007; Kurokawa et al., 2004; Morgan, 2004; Uchikawa et al., 2003) . Furthermore, Otx2 and Six3, for example, act both as transcriptional activators and repressors, interacting with other co-factors (Heimbucher et al., 2007; Kelley et al., 2000; Kobayashi et al., 2001; Lopez-Rios et al., 2003; Zhu et al., 2002) , which might help in specialising their regional functions. Another relevant element of diversification is the level of gene expression. Heterozygous loss-of-function mutations in the human SOX2 or OTX2 genes can cause independent eye (Ragge et al., 2005a; Ragge et al., 2005b) or hypothalamic (Dateki et al., 2010; Tziaferi et al., 2008) defects without affecting other forebrain regions, which suggests a differential sensitivity of forebrain territories to gene dosage. Whether and how these different factors cooperate during normal development to adapt individual gene activity to the specific needs of the different forebrain regions is still unexplored.
The homeobox TF Six3 is a suitable candidate to address the above questions. Its expression is evolutionary conserved in the anterior forebrain (Bovolenta et al., 1998; Loosli et al., 1998; Lopez-Rios et al., 1999; Oliver et al., 1995; Seo et al., 1999) , where it is required for the development of the telencephalon (Kobayashi et al., 1998; Lagutin et al., 2003) , the eye (Carl et al., 2002; Loosli et al., 1999; Zhu et al., 2002; Zuber et al., 2003) and the hypothalamus (Gaston-Massuet et al., 2008; Jeong et al., 2008; Lavado et al., 2008; Ohyama et al., 2005) . Still, it is unclear how it mediates regional differences. Among the vertebrate orthologues, Six3.2, one of the two medaka fish (Oryzias latipes) paralogues, offers particular advantages because its precise cis-regulatory code has been well characterised (Conte and Bovolenta, 2007) , facilitating the identification of region-specific trans-acting factors. Furthermore, in teleosts, specific mRNA levels can be easily experimentally modulated (Carl et al., 2002) .
Exploiting these advantages, here we delineate a gene regulatory network in which Six3.2 diversifies its activity in the forebrain. We demonstrate that differential expression levels of Six3.2, operating under the differential control of Sox2, are likely to pattern the forebrain by directly activating the telencephalic determinant Foxg1 (Tao and Lai, 1992) , restraining, at the same time, the expression of the hypothalamic and retinal determinant Rx3 (Deschet et al., 1999; Loosli et al., 2001; Stigloher et al., 2006) . We also show that Sox2, besides controlling Six3.2 expression, activates that of Rx3, thus establishing a four gene 'kernel' that contributes to forebrain specification.
MATERIALS AND METHODS

Medaka stocks
Wild-type (wt) Oryzias latipes of the cab strain were maintained in an inhouse facility (28°C on a 14/10-hour light/dark cycle). Embryos were staged according to Iwamatsu (Iwamatsu, 2004) .
In silico analysis
Jaspar (http://jaspar.genereg.net) and rVista (http://rvista.dcode.org/) were used to identify putative TF binding sites (BSs) within the Six3.2 regulatory region, setting the core identity to ≥90%. Positive sites were further screened for evolutionary conservation by phylogenetic footprinting among different teleost species (Fugu rubripes, Gasteropus aculeatus, Tetraodon nigroviridis and Danio rerio) using mVista (http://genome.lbl.gov/vista/ mvista/about.shtml) and multalin (http://multalin.toulouse.inra.fr/multalin). Identified candidates were further selected using expression pattern information available in the literature and in the ZFIN database (http://zfin.org).
Plasmid construction
The thymidine kinase (TK) minimal promoter was cloned into the pGL3-basic vector (Promega) to generate pGL3bTK, into which was then inserted PCR-amplified combinations (supplementary material Table S1) of the characterised Six3.2 regulatory elements (Conte and Bovolenta, 2007) . Final constructs were: cI, comprising the entire Six3.2 regulatory region; cII, lacking the ABC elements; cIII, cIV and cV, respectively containing the D and IL elements or the TK minimal promoter alone (Fig. 1) . Deletion constructs of the D element (cVI-cXI) were generated by PCR amplification from cIII using specific primers (supplementary material Table S1 ). Mutagenesis of the putative Sox BS was performed using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene) using specific primers (cXII; supplementary material Table S1 ) and following the manufacturer's instructions. The pd51LucII vector carrying the characterised 258 bp Nestin enhancer (Tanaka et al., 2004 ) was a kind gift of S. Nicolis (University of Bicocca, Milan). The 3.5 kb Rx3 regulatory region and full-length medaka Sox2, Six3.1 and Six3.2 were amplified by PCR and cloned into the pGL3b and pCMV-myc vectors (Clontech). For in vitro RNA transcription, myc-Sox2, myc-Six3.1 and myc-Six3.2 were subcloned into the pCS2+ vector.
RNA extraction and quantitative (Q) PCR
Total RNA from stage (st) 19 injected embryos was extracted using Trizol (Invitrogen) and treated with DNase I (Roche). cDNAs were obtained using the First-Strand cDNA Synthesis Kit (GE Healthcare). RT-PCR reactions were run in triplicate in 96-well plates with the SYBR Green PCR Master Mix using an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). Q-RT-PCR reactions were performed with 2 ml cDNA, which was diluted tenfold for 18S rRNA amplifications used for normalisations. Primers specific for each of the analysed targets (supplementary material Table S1) were designed using Primer3Plus (http://www.primer3plus.com/). Analysis of the Q-RT-PCR assays was performed using the 7500 system SDS software (v2.0.1, Applied Biosystems). The SYBR Green-double-stranded DNA complex signal was normalised to the passive reference dye (ROX) to correct for non-PCRrelated well-to-well fluorescence fluctuations. Experiments were independently replicated at least three times.
Cell transfection and luciferase assay
BHK21 or P19 cells were co-transfected using the Fugene HD transfection reagent (Roche) in MEMa-Glutamax medium (Gibco) and cultured for 48 hours in the presence of 5% foetal calf serum. For luciferase assays, cells were transfected with the reporter (50 ng) and Renilla luciferase (10 ng) plasmids and different amounts (25-200 ng) of the effector plasmid. Experiments were performed in triplicate and replicated at least three times as described (Conte et al., 2010b) . Data are presented as fold induction of the luciferase activity observed in the control vector normalised to 1. Basal activity of the cI-cV construct is illustrated in supplementary material Fig. S2C .
Chromatin immunoprecipitation (ChIP) assays
ChIPs were performed as described (Conte et al., 2010b) , using P19 cells transfected with a 3:1 ratio of reporter:effector plasmids (10 mg total). Fold enrichment was expressed as the ratio of myc-Sox2 to IgG signal and calculated with the formula 2 -(Ct) , where CtCt c-Myc -Ct IgG .
RNA and morpholino antisense oligonucleotide (MO) injections
Sox2, Six3.1 and Six3.2 synthetic mRNAs were obtained and injected as described (Conte et al., 2010b) , using concentrations ranging from 5-50 ng, 20-80 ng and 1.0-30 ng, respectively. Selected working concentrations were 20 ng (Sox2), 20-40 ng (Six3.1) and 1.0-10 ng (Six3.2). MOs (supplementary material Table S1) (Gene Tools) were designed against the 5ЈUTR of Sox2, Six3.1 (Carl et al., 2002) and Six3.2. A standard control MO (Gene Tools) or an MO carrying five mismatches was used as control (generically referred to as cMO). The specificity and efficiency of each MO were determined as described (Eisen and Smith, 2008; Ruiz et al., 2009) . cMO had no effects at any of the tested concentrations (20-300 mM) and embryos were undistinguishable from wt. Sox2- MO, .2-MO were tested at concentrations ranging from 50-300, 20-80 and 12.5-120 mM, and the selected working concentrations were 200, 20-40 and 20-60 mM, respectively. None of the MOs had off-target effects (Robu et al., 2007) at these concentrations. MOs were injected into two-cell stage embryos. At least three independent experiments were performed for each marker and condition.
In situ hybridisation
Whole-mount in situ hybridisations were performed as described (LopezRios et al., 2008) . Antisense and sense riboprobes for the medaka Fgf8, Rx3, Rx2, Six3.2, Fezl, Foxb1.2, Foxg1, Sox1, Sox2, Sox3, Sox19, Dmbx1, Emx3, Nkx2.1, Nkx2 .2 and Arx were used. Probes were generated from cDNA amplified from st16-24 embryos using specific primers (supplementary material Table S1 ) and cloned into the pDrive vector (Qiagen). mRNAs were detected with NBT/BCIP (purple), INT/BCIP (orange/dark red), BCIP (light blue) or Fast Red (fluorescent red) substrates (Roche).
Cell proliferation analysis
Embryos were immunostained with anti-phospho-histone H3 antibodies (Roche Diagnostics) as described (Ruiz et al., 2009) . Immunopositive cells were counted with the aid of ImageJ software (NIH) and normalised to the total area of each territory. Fig. S3A ).
Image analysis and quantification
As is the case with other TFs belonging to the same family, SoxB factors share a high degree of conservation in their DNA BS, suggesting a possible functional redundancy. Indeed, zebrafish sox2, sox3, sox19a and sox19b have been shown to act redundantly at an early stage of neural specification (Okuda et al., 2010) . We thus considered that the medaka orthologues of the SoxB1 subfamily could be potential regulators of Six3.2 expression.
Comparative in silico genome searches identified the medaka orthologues of all SoxB genes, although only one Sox19 paralogue was found (supplementary material Fig. S3A ).
RESEARCH ARTICLE
Development 139 (1) 
DEVELOPMENT
Expression analysis revealed that Sox2 mRNA distribution coincided with that of Six3.2 in the ANP from gastrulation stages ( Fig. 1E,I ), as described in other species (Papanayotou et al., 2008; Wood and Episkopou, 1999) . Although broadly expressed throughout the entire neural tube, Sox2 was, as with Six3.2, differentially distributed in the forebrain, with high levels in the telencephalic domain (Fig. 1F ,G,J,K,N,O; supplementary material Fig. S3C ,G) and lower and graded (anterior high to posterior low ) levels in the optic vesicles (Fig. 1F ,G,J,K). Both genes also overlapped in the basal hypothalamus (Fig. 1N,O) , albeit with different intensities. Sox3 and Sox19 were also expressed in the forebrain but were virtually absent from the optic vesicles (supplementary material Fig. S3D ,E,H,I), whereas Sox1 colocalised with Six3.2 only in the presumptive hypothalamic region at st20 (supplementary material Fig.  S3B ,F). According to this spatiotemporal expression, Sox2 appeared to be the most suitable candidate to activate Six3.2.
To corroborate this hypothesis, we compared the ability of Sox2 to transactivate luciferase reporter plasmids carrying different combinations of the Six3.2 regulatory elements (Fig. 1P ). Cotransfection of increasing concentrations of Sox2 in P19 (Fig. 1Q ) or BHK21 (supplementary material Fig. S2D ) cells transactivated those constructs carrying the D or IL HNCE. Furthermore, the cII construct, lacking the ABC HNCEs, was more efficiently activated by Sox2 than cI ( Fig. 1Q ), confirming the predicted existence of a silencer in the A element (Conte and Bovolenta, 2007) . Notably, Sox3 and Sox1 showed only a lower or no transactivation activity on the cIII or cII constructs, when transfected into BHK21 or P19 cells (supplementary material Fig. S2D ,E), although they activated, as efficiently as Sox2, a construct containing a characterised Nestin enhancer that responds to all SoxB1 genes (Tanaka et al., 2004) . Similarly, Sox21, a SoxB2 representative, did not appear to modify basal (supplementary material Fig. S2E,F) or Pax6-activated (not shown; see below) reporter expression from the cII or cIII constructs.
The D regulatory element contains clusters of six potential Sox BSs (S1-S6; supplementary material Fig. S2A ,B), the sequence of which has recently been proven to functionally bind Sox2 in other contexts (Engelen et al., 2011) . When deletion constructs (cVI-cXI) lacking different Sox BSs were probed with Sox2, reporter activation was virtually abolished in all constructs lacking the S2-S5 BS region (supplementary material Fig. S2G ). Consistently, specific mutagenesis of S3-S5 had the same effect (supplementary material Fig. S2G ), although the mutated enhancer responded efficiently to other characterised Six3.2 activators such as Pax6 (data not shown), further supporting the conclusion that these BSs are specifically required for Sox2-mediated activation.
To verify whether Sox2 binds to the Six3.2 regulatory region in vivo, we performed ChIP assays using st16-18 medaka embryos. As expected for these stages, Sox2-specific antibodies revealed a fourfold enrichment of Sox2 on the D but not the IL element (Fig.  1R) , which is active only at later stages. However, when P19 cells were co-transfected with the cII construct and a Sox2-myc-tagged expression plasmid, anti-myc antibody, but not control IgG, revealed a significant enrichment of Sox2 on both the D and IL enhancers (Fig. 1S ), consistent with a report showing that Sox2 occupies the Six3 promoter region in mouse embryonic stem cells (Boyer et al., 2005) .
According to the idea that Sox2 is a direct and physiological regulator of Six3.2 expression, MO-mediated (200 mM) knockdown of Sox2 caused a significant reduction of the total Six3.2 mRNA levels compared with control (cMO)-treated embryos ( Fig. 2A) . By in situ hybridisation, Six3.2 expression appeared strongly diminished throughout the prosencephalon (Fig. 2C,D ,F,G). 
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Conversely, injections of Sox2, but not EGFP, mRNAs (20 ng/ml) significantly increased the levels of Six3.2 transcripts (Fig. 2B) , the localisation of which was caudally expanded (Fig. 2C,E,F,H) . Sox2 morphants were also characterised by a significant decrease in the mRNA levels of the Six3.1 paralogue ( Fig. 2A) , a reduction that was mostly evident in the subpallium, diencephalon and hypothalamus (Fig. 2I ,J,L,M). However, Sox2 gain-of-function had a negative effect on total Six3.1 mRNA levels (Fig. 2B) , probably owing to the small size of the optic vesicles and altered expression in the diencephalon and hypothalamus (Fig. 2I,K,L,N) . Because Sox2 and Six3.1 expression do not overlap in the latter regions at this stage (Fig. 1C,K (Wilson and Houart, 2004) . Consistent with an important role of Sox2 in establishing neural identity (Uchikawa et al., 2011) , st16 Sox2 morphants displayed reduced telencephalic, retinal and hypothalamic fields, identified by the expression of Fgf8/Fezl/Foxg1, Rx3 and Foxb1.2, respectively (Fig. 3) . Notably, this reduction was more evident in the prospective telencephalic domain, where the expression of Fezl and Fgf8 was strongly reduced (Fig. 3A,B ,F,G) and, in the case of Fgf8, also slightly delayed when compared with controls (not shown). Supporting that Six3.2 is among Sox2 targets, Six3.2 morphants showed a similar, although less evident, phenotype, with a pronounced reduction of the telencephalic versus retinal field but, surprisingly, an enlarged hypothalamic domain (Fig. 3C,H) . Conversely, Sox2 or Six3.2 overexpression expanded the telencephalic field but reduced the Rx3-positive domain (Fig. 3A,D-F,I ,J). Furthermore, as observed in the respective morphants, Sox2 and Six3.2 had opposite effects in the hypothalamus when overexpressed (Fig. 3F,I,J) .
Similarities between the phenotypes induced by the manipulation of Sox2 and Six3.2 expression were more apparent at slightly later stages (st18-20), when Sox2 and Six3.2 morphants were characterised by significantly reduced retinal (Rx3 or Rx2 positive) and telencephalic (Fgf8-, Emx3-or Foxg1-positive) primordia, when compared with cMO-injected embryos ( Fig. 3K-M; Fig. 4A,B,D ,E,G-J; supplementary material Table S2 ). Conversely, Sox2 overexpression caused telencephalic enlargement and retinal reduction (Fig. 4C,F,I ,K; supplementary material Table  S2 ), whereas other caudal morphogenetic events were not significantly affected (not shown).
A reduction of the retinal primordia upon Sox2 or Six3.2 overexpression was somewhat unexpected because both genes are required for eye formation in mammals and Six3.1 expands the eye field and induces the formation of ectopic retina-like tissue (Lagutin et al., 2003; Loosli et al., 1999; Lopez-Rios et al., 2003; Taranova et al., 2006) . We therefore hypothesized that Sox2-mediated regulation of Six3.2 must predominantly favour telencephalic development at the expense of the retina, overriding Six3.1 activity in this tissue. If this were the case, Six3.2 but not Six3.1 should preferentially counteract the impaired telencephalic development observed in Sox2 morphants. Indeed, co-injection of Sox2-MO with increasing concentrations of Six3.2 mRNA progressively rescued telencephalic and retinal size ( Fig. 4J ; supplementary material Table S2 ), but the levels necessary to rescue the retina were lower than those required for the telencephalon ( Fig. 4J ; supplementary material Table S2 ). Increasing Six3.1 mRNA doses instead did not modify the size of the telencephalon in Sox2 morphants but did partially rescue the retina ( Fig. 4L ; supplementary material Table S2 ). Similarly, when co-injected, Six3.2-MO but not Six3.1-MO counteracted the Sox2 mRNA-mediated alterations of the retinal and telencephalic domains in a concentration-dependent and region-specific manner ( Fig. 4K,M ; supplementary material Table S2 ): low Six3.2-MO doses (20 mM) partially rescued telencephalic enlargement but had no effect on the retina ( Fig. 4K; supplementary Table S2 ).
Together, these data indicate that, in medaka, Six3.2 levels differentially affect the specification of the telencephalon and the retina. The first depends on high Six3.2 activity, whereas retinal development is likely to rely on Six3.1 function (Carl et al., 2002) but requires only low Six3.2 activity.
To corroborate this dose-dependent regulation of telencephalic and retinal development, we overexpressed different concentrations of Six3.2 mRNA. When compared with GFP-injected controls, Six3.2 gain-of-function resulted in different phenotypes characterised by either reduced or enlarged optic vesicles (Fig. 5) . Embryos with reduced Rx-positive territories presented a significant expansion of the Fgf8-or Emx3-positive telencephalon ( Fig. 5C ; supplementary material Table S4 ), whereas embryos with enlarged Rx-positive tissue showed either reduced (Fig. 5B) or enlarged (Fig. 5D ) telencephalic marker expression. Although a mixture of at least two phenotypes was always observed, the relative proportion of each phenotype differed significantly among embryos injected with distinct Six3.2 mRNA doses (supplementary material Table S4 ). At low doses (2.5 ng/ml) the majority of the embryos showed enlarged retinas with a smaller telencephalon (Fig. 5B,E) , whereas at intermediate doses (5 ng/ml) most embryos resembled those observed upon Sox2 overexpression, with small optic vesicles and enlarged telencephalon (Fig. 5C,F) . Surprisingly, at high Six3.2 mRNA levels (7.5 ng/ml) embryos with both telencephalic and retinal enlargement predominated (Fig. 5D,G) . This phenotype resembles that observed upon Six3 or Six6 overexpression (Loosli et al., 1999; Lopez-Rios et al., 2003; Zuber et al., 2003) , suggesting that at high doses Six3.2 might acquire functions that are normally exerted by the related Six3.1 and Six6.
Six3.2 represses hypothalamic specification by a Sox2-independent mechanism Taken together, these results support a model in which Sox2 differentially activates Six3.2 in the forebrain. Higher Six3.2 levels would promote telencephalic specification while limiting retinal marker expression, which, instead, would only require low Six3.2 doses.
Sox2 and Six3.2 were also co-expressed in the hypothalamus (Fig. 1N,O) , where alteration of Sox2 expression also appeared to modify Six3.2 mRNA levels ( Fig. 2F-H (Fig. 6A,B ,F,G). Conversely, injections of increasing concentrations of Six3.2 mRNA progressively reduced the hypothalamic and Dbmx1-positive mesencephalic domains but expanded the prethalamic region (Fig. 6A ,B,C,F). Sox2 overexpression instead caused a notable increase of the Nkx2.1-positive hypothalamus and had no effect on the diencephalic or mesencephalic domains (Fig. 6A ,E,F), whereas in Sox2 morphants the hypothalamus, and to a much lower extent the prethalamus and the mesencephalon, were decreased (Fig. 6A,D ,F,G; supplementary material Table S3 ). Furthermore, and in contrast to what was observed in the telencephalon, Six3.2 mRNA (1.0 and 2.5 ng/ml) did not rescue the reduced hypothalamic and mesencephalic size of Sox2 morphants; rather, when compared with Sox2 morphants, high Six3.2 doses further reduced the Nkx2.1-and Dmbx1-positive territories and expanded the prethalamic domain (Fig. 6G) . These results suggest that Six3.2 normally antagonises hypothalamic development via a mechanism that seems independent from Sox2 function. Sox2, by contrast, promotes hypothalamic development by activating other target genes.
Increased telencephalic precursor proliferation and direct activation of Foxg1 and Rx3 may account for Sox2 and Six3.2 activities in the anterior forebrain Taken together, our results suggested that graded Six3.2 levels pattern the forebrain along the anterior-posterior axis, rostrally upon Sox2 control and caudally with a Sox2-independent mechanism. To explain these observations we took into consideration two non-mutually exclusive mechanisms.
First, differential mitotic rates could account for the observed forebrain alterations because both Sox2 and Six3.2 control neural precursor proliferation (Del Bene et al., 2004; Ferri et al., 2004; Gestri et al., 2005; Taranova et al., 2006) . Evaluation of regional restricted proliferation using phospho-histone H3 immunostaining revealed that Sox2 or Six3.2 overexpression specifically promoted the proliferation of telencephalic precursors but, respectively, barely affected or reduced those of the retina. Their knockdown, instead, reduced proliferation in both domains when compared with controls (supplementary material Fig. S4 ). This suggests that Sox2-mediated activation of Six3.2 is likely to recruit more proliferating progenitors to the telencephalic field.
Second, and to corroborate the above possibility, we considered that Six3.2 could impose tissue identity by controlling the expression of other anterior forebrain determinants. Recent studies in zebrafish showed that rx3 promotes retinal specification at the expense of the telencephalon, repressing, directly or indirectly, foxg1 activity (Stigloher et al., 2006) . Notably, increasing Six3.2 mRNA concentrations significantly reduced and totally abolished Rx3 expression in the retina and hypothalamus, respectively (Fig.  7A-H; supplementary material Table S4 ), even at concentrations at which other hypothalamic markers, including Nkx2.1, were still observed (Fig. 6A,C) . Conversely, Six3.2 overexpression significantly expanded Foxg1 expression even at low doses ( Fig.  7A-H ; supplementary material Table S4 ), but had milder effects on the expansion of other telencephalic markers such as Fgf8 and Emx3 ( Fig. 5E,F ; supplementary material Table S4 ). Consistently, the levels of Rx3 mRNA were upregulated fourfold in Six3.2 morphants, whereas those of Foxg1 were threefold lower than those detected in GFP-injected embryos (Fig. 7I) .
Thus, Six3.2 appeared to counteract the activity reported for Rx3 (Stigloher et al., 2006) , and its marked effects on Rx3 and Foxg1 expression pointed to a possible direct regulation. Phylogenetic footprinting of the vertebrate Foxg1 and Rx3 loci identified HNCEs containing putative conserved Six3 BSs (supplementary material Fig. S5 ). ChIP assays performed in P19 cells confirmed that transfected Six3.2-myc bound with high enrichment to HNCE-1 of the co-transfected Rx3 medaka promoter and to HNCE-1 of the endogenous Foxg1 regulatory region (Fig. 7J) . Previous studies have shown that Sox2 binds to, and transactivates, an enhancer
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Development 139 (1) present in the Xenopus Rx1 locus (Danno et al., 2008) . The medaka Rx3 HNCE-1 also contains a Sox BS (supplementary material Fig.  S5C ) to which Sox2 bound with fourfold enrichment in st16-18 medaka embryos (Fig. 7K) , offering a possible explanation for the Sox2-mediated expansion of the hypothalamic domain (Fig.  6A ,E-G). Together, these studies suggest a gene regulatory network in which Six3.2, together with Sox2, operates to pattern the vertebrate forebrain (Fig. 8) . Disturbance of the gene network balance causes patterning alterations.
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DISCUSSION
The identification of gene regulatory networks responsible for the specification of cell identity is important with a view to understanding how embryonic development is driven and provides fundamental information that can be exploited to reprogram stem cells for tissue repair. Yet disentangling cell-specific genetic programmes is a major challenge, especially for vertebrate tissues because master regulatory genes have often been co-opted to specify cells of related embryological origin. Combining genomic and functional approaches we show that different levels of Six3.2, acting both as a transcriptional activator and repressor, contribute to the specification of the distinct forebrain domains. In doing so, we have highlighted a novel role for Sox2 in forebrain development and delineated a possible hierarchy of four TFs -Sox2, Six3.2, Foxg1 and Rx3 -that act to define the telencephalic, retinal and hypothalamic domains within the ANP (Fig. 8) .
Specification and patterning of the anterior forebrain require sustained inhibition of Wnt signalling (Wilson and Houart, 2004) . Soluble Wnt antagonists, the repressor activity of Tcf3 (a member of the Tcf/Lef family of TFs) and Six3 constrain Wnt canonical signalling, promote telencephalic and retinal fates and delimit the diencephalic territory. Abrogation of the function of any of these molecules increases canonical Wnt signalling, enlarges the diencephalon and impairs anterior forebrain formation (Houart et al., 2002; Kim et al., 2000; Lagutin et al., 2003) . We provide compelling genomic and functional evidence that Sox2 is an additional major regulator of anterior forebrain development by directly activating Six3.2. Although, Sox1 and Sox3 showed a lower transactivation activity than Sox2 or no transactivation activity -especially in P19 cells, in which appropriate Sox co-factors might exist and contribute to refine transactivation -on the Six3.2 regulatory region, our study does not exclude the possibility that SoxB1 factors other than Sox2 might contribute to Six3.2 regulation. Indeed, SoxB1 genes have been shown to act redundantly in other contexts (Okuda et al., 2010; Tanaka et al., 2004) and, in medaka, their partially overlapping distribution (supplementary material Fig. S3 ) implies a similar role in forebrain patterning. Nevertheless, specific distribution, differential affinity for the Sox BS and unique protein-protein interactions (Kamachi et al., 2000) may underlie the preponderant role of Sox2 in medaka anterior forebrain specification uncovered here. Consistent with this idea, SoxB1 genes have recently been shown to activate distinct repertoires of target genes during Xenopus neurogenesis (Archer et al., 2011) .
Sox2 function has been extensively investigated because of its capacity to confer pluripotency to embryonic and reprogrammed stem cells (Avilion et al., 2003; Masui et al., 2007; Takahashi and Yamanaka, 2006) , but the consequent early embryonic lethality of homozygous Sox2 mutants (Avilion et al., 2003) has hampered the establishment of its function in the CNS. Conditional inactivation of Sox2 in the embryonic mouse brain, after forebrain patterning has occurred, causes only minor defects at birth, although postnatal neurogenesis in the hippocampus is severely affected (Favaro et al., 2009) . Our study reveals a novel and early aspect of Sox2 function in the forebrain. Knockdown of Sox2 impairs telencephalic development and decreases Six3.2 expression, whereas Sox2
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Development 139 (1) overexpression has the opposite effects. These phenotypes are progressively rescued by the co-injection of increasing concentrations of Six3.2 mRNA and MO, respectively, whereas similar experiments using the Six3.1 paralog were less efficient, especially when the Six3.1-MO was used. These findings, together with luciferase and ChIP data, indicate that Six3.2 is a major target of Sox2 in the telencephalon and that telencephalic specification requires high Six3.2 activity. Notably, modifications to Sox2 and Six3.2 expression also interfere with retinal development, but with notable differences to their effects on the telencephalon. First, a reduction in retinal size was evident with gain-and loss-of-function of both genes, similar to what has been reported for mice with high and low Pax6 levels (Schedl et al., 1996) , suggesting that, within the forebrain, the retina might be particularly sensitive to extreme gene dosage. Second, low Six3.2 mRNA concentrations were sufficient to normalise the retina of Sox2 morphants. Third, whereas Six3.2 knockdown could easily counterbalance the effects of Sox2 overexpression, co-injections of Six3.1-MO had almost the opposite effect. Therefore, proper retinal formation requires lower Sox2 and Six3.2 levels than those necessary to pattern the telencephalon. This interpretation is supported by the mRNA distribution of Six3.2 and Sox2 in the forebrain, which is characterised by higher levels in the telencephalon than in the retina. Distinct dose-dependent Sox2 functions are not unique to the forebrain. Trachea and oesophagus patterning is also Sox2 dependent, but Sox2 hypomorphic embryos develop a trachea with oesophagus-like morphology, indicating that the trachea requires lower Sox2 levels (Que et al., 2007) .
What determines these graded levels is unclear but the control might be post-transcriptional. MicroRNAs with retinal-restricted expression have been reported (Alfano et al., 2005; Conte et al., 2010a; Huang et al., 2008) , pointing to this mechanism as an attractive possibility. Graded expression might be also a direct consequence of Sox2 regulation. Sox2 is expressed with the same graded intensity in the anterior forebrain and the D HNCE contains several Sox BSs, for which Sox2 might have different affinities, differentially contributing to full Six3.2 activation. The activation of cis-regulatory modules by concentration gradients of TFs depends upon the use of high-and low-affinity DNA BSs, where only high TF concentrations can activate the low-affinity sites (Bonn and Furlong, 2008; Papatsenko and Levine, 2005) . It is thus conceivable that only high Sox2 levels in the anterior-most forebrain can fully activate the D enhancer, providing the required Six3.2 activity for telencephalic development.
The telencephalic and retinal domains are initially closely related because manipulations of canonical Wnt signalling simultaneously affect both fields (Wilson and Houart, 2004) . Activation of non-canonical Frizzled receptors and expression of Sfrp1 and Rx3 contribute to define the retinal territory, segregating it from the telencephalon in teleosts (Cavodeassi et al., 2005; Esteve et al., 2004; Lopez-Rios et al., 2008; Stigloher et al., 2006) . Our study, showing that Sox2 and Six3.2 alterations always affect the telencephalon more than the retina, has two important implications.
First, it suggests that the preponderant role of Sox2/Six3.2 in medaka telencephalic development counteracts the activity of retinal and hypothalamic determinants such as Rx3 (Stigloher et al., 2006) . Supporting this interpretation, we show that Six3.2 binds to the regulatory region and directly controls the expression of the telencephalic determinant Foxg1 (Tao and Lai, 1992) , providing experimental evidence to support previous suggestions in chick (Kobayashi et al., 2002) . Six3.2 also binds to an Rx3 enhancer but is likely to repress its expression, at least in the hypothalamus. Rx3, in turn, seems to antagonise the telencephalic determinants Foxg1 and Fez1 and to activate expression of the retinal determinant Mab21l2 (Kennedy et al., 2004; Stigloher et al., 2006) . Therefore, we propose a regulatory network (Fig. 8) in which high levels of Six3.2 expression, under the direct control of Sox2, repress Rx3 expression and thereby favour that of Foxg1 in the telencephalon. In the retina, however, a lower Six3.2 activity would not be sufficient to repress Rx3, the activation of which would consequently repress Foxg1-mediated telencephalic fate, as previously suggested (Kennedy et al., 2004; Stigloher et al., 2006) . In support of this hypothesis, a recent study has shown that differences in the extent of the Six3 expression domain positively correlate with the size of the telencephalon in cichlid fishes (Sylvester et al., 2010 compatible with studies of other Six3 orthologues showing that activator and repressor roles depend on context-specific interactions. Indeed, Six3 binds a variety of proteins, including other TFs (Tessmar et al., 2002) , transcriptional co-repressors of the Groucho family (Kobayashi et al., 2001; Lopez-Rios et al., 2003) , coactivators such as EYA4 (Abe et al., 2009 ) and components of the chromatin remodelling complexes, including MTA1 and HDAC2 (Manavathi et al., 2007) .
Second, our results show that the medaka Six3 paralogues have undergone at least partial subfunctionalisation, with a major function for Six3.1 in the eye and significant involvement of Six3.2 in telencephalon formation. Six3.2 gain-of-function did not induce the formation of ectopic retinal tissue, in contrast to the effect of Six3.1 overexpression (Loosli et al., 1999; Lopez-Rios et al., 2003) , but rather appeared to recruit proliferating progenitors into the telencephalic domain. Conversely, alterations of Six3.1 expression had a clear influence on retinal development but only a marginal effect on that of the telencephalon (Carl et al., 2002; Loosli et al., 1999; Lopez-Rios et al., 2003) . The two medaka Six3 paralogues have a virtually identical homeobox sequence, which probably explains why high Six3.2 concentrations cause a phenotype similar to that observed upon Six3.1 overexpression (Fig. 5G,J) . However, there are also appreciable divergences in the Six and C-terminal domains, which are known to mediate binding to various interactors (Kumar, 2009; Weasner and Kumar, 2009 ). This suggests that the two paralogues normally participate in different transcriptional complexes. Functional differences might also be linked to Sox2-mediated differential regulation, as Sox2 strongly activates Six3.2 but seems to reduce, directly or indirectly, Six3.1 expression (Fig. 2) . Furthermore, Sox2 overexpression never expanded retinal size, which might reflect its opposing effects on Six3.2 and Six3.1 expression, as well as the influence of Sox2 on other, as yet undefined, genes implicated in telencephalic versus eye and hypothalamic fate acquisition.
Whether Six3.1 and Six3.2 exhibit reciprocal regulation, refining telencephalic and retinal differences, is unclear. Injections of Six3.2-MO appeared to lower Six3.1 mRNA levels and vice versa, and Six3.2 activates the regulatory region of Six3.1 in luciferase assays (L.B. and P.B., unpublished). The existence of this loop could explain why low doses of Six3.2 reduce the telencephalon and expand eye size, possibly favouring the proposed Six3.1-mediated maintenance of Rx3 expression (Carl et al., 2002) . Changes in relative retinal and telencephalic size are also related to cell proliferation. Sox2 has been shown to maintain a neural progenitor state by repressing proneural genes (Agathocleous et al., 2009; Wen et al., 2008) , and Six3 orthologues, including Six3.1, promote cell proliferation with transcription-dependent and -independent mechanisms (Appolloni et al., 2008; Del Bene et al., 2004; Gestri et al., 2005) . The more pronounced contribution of Sox2 and Six3.2 to telencephalic progenitor proliferation, as suggested by the overexpression of both genes, is however intriguing and again suggests that participation in different transcriptional complexes might best explain the paralogue and regional differences.
This does seem to be the case for the hypothalamus. In humans, SOX2 heterozygous or de novo mutations are associated with eye defects and hypopituitarism, and mouse embryos with reduced Sox2 expression have small pituitary glands (Kelberman et al., 2006) . Providing a molecular mechanism for these defects, we show that Sox2 binds to an Rx3 HNCE, as previously shown for the related Xenopus Rax orthologue (Danno et al., 2008; Kennedy et al., 2004) , and, upon overexpression, expands the hypothalamic domain. Although not tested, Sox2 effects in the hypothalamus might also be mediated by Nkx2.1 and Shh, which are, respectively, postulated and proven targets of Sox2 activity (Favaro et al., 2009; Que et al., 2007) . Despite expression overlap and expansion of the Six3.2 domain upon Sox2 injection, Six3.2 gainof-function resulted in an opposite phenotype, with a marked reduction of the Rx3-and Nkx2.1-positive hypothalamic region. This suggests that, in the hypothalamus, Sox2 and Six3.2 act in at least partially independent pathways and are likely to compete for Rx3 and possibly Nkx2.1 regulation (Fig. 8) . This differs from what has been observed in mammals, where Six3 positively contributes to hypothalamic development (Gaston-Massuet et al., 2008; Jeong et al., 2008; Lavado et al., 2008) . This discrepancy could be easily explained by the proposed subfunctionalisation of the medaka fish paralogues, whereby Six3.2 and Six3.1 would respectively favour dorsal and ventral forebrain development. According to this hypothesis, hypothalamic development (not shown) and ventral prosencephalic specification (Carl et al., 2002) would be impaired in Six3.1 morphants.
In conclusion, our study highlights the role of a TF core composed of Sox2, Six3.2, Foxg1 and Rx3 in medaka forebrain development, uncovering new aspects of Six3 and Sox2 function. Similar regulatory mechanisms might be at least partially conserved in mammals, as suggested by the phenotypes caused by loss-of-function or haploinsufficiency of Six3 or Sox2 (Geng et al., 2008; Kelberman et al., 2008; Morrison et al., 2002; Suh et al., 2010) . 
